Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.

Crochiere ML, Hannus S, Hansen K, Becker F, Baloglu E, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2017 Nov 30;8(66):110503-110516. doi: 10.18632/oncotarget.22801. eCollection 2017 Dec 15.

2.

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.

Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, Crochiere M, Italiano JE Jr, Landesman Y.

Blood. 2017 Aug 31;130(9):1132-1143. doi: 10.1182/blood-2016-11-752840. Epub 2017 Jun 19.

PMID:
28630120
3.

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.

Rane C, Senapedis W, Baloglu E, Landesman Y, Crochiere M, Das-Gupta S, Minden A.

Sci Rep. 2017 Feb 15;7:42555. doi: 10.1038/srep42555.

4.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

5.

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere ML, Baloglu E, Klebanov B, Donovan S, Del Alamo D, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Jan 12;7(2):1863-77. doi: 10.18632/oncotarget.6495.

6.

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere M, Kashyap T, Kalid O, Shechter S, Klebanov B, Senapedis W, Saint-Martin JR, Landesman Y.

BMC Cancer. 2015 Nov 17;15:910. doi: 10.1186/s12885-015-1790-z.

7.

Therapeutic Potential of Targeting PAK Signaling.

Senapedis W, Crochiere M, Baloglu E, Landesman Y.

Anticancer Agents Med Chem. 2016;16(1):75-88. Review.

PMID:
26081410
8.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A.

Mol Cancer Ther. 2015 Jul;14(7):1570-81. doi: 10.1158/1535-7163.MCT-15-0104. Epub 2015 May 1.

9.

Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.

Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, Crochiere M, Landesman Y, Daelemans D.

Chem Biol. 2015 Jan 22;22(1):107-16. doi: 10.1016/j.chembiol.2014.11.015. Epub 2015 Jan 8.

10.

Identification of unique molecular subdomains in the perichondrium and periosteum and their role in regulating gene expression in the underlying chondrocytes.

Bandyopadhyay A, Kubilus JK, Crochiere ML, Linsenmayer TF, Tabin CJ.

Dev Biol. 2008 Sep 1;321(1):162-74. doi: 10.1016/j.ydbio.2008.06.012. Epub 2008 Jun 16.

11.

Perichondrial-mediated TGF-beta regulation of cartilage growth in avian long bone development.

Crochiere ML, Kubilus JK, Linsenmayer TF.

Int J Dev Biol. 2008;52(1):63-70.

12.
13.

Multiple mechanisms of perichondrial regulation of cartilage growth.

Di Nino DL, Crochiere ML, Linsenmayer TF.

Dev Dyn. 2002 Nov;225(3):250-9.

14.

Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein.

Wang L, Sunahara RK, Krumins A, Perkins G, Crochiere ML, Mackey M, Bell S, Ellisman MH, Taylor SS.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3220-5.

Supplemental Content

Loading ...
Support Center